TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically or cytologically conﬁrmed colorectal or breast cancer receiving capecitabine monotherapy or combination chemotherapy.~* Eligible patients were within 18-70 years of age.~* ECOG score was 0-2.~* Left ventricular ejection fraction (LVEF) \> 50%.~* There was no serious persistent toxicity to capecitabine treatment before screening (laboratory tests ≤ grade 1 (NCI CTCAE 5.0 standard)~* Hand-foot syndrome ≤ grade 2 after recovery from the previous treatment period).~Exclusion Criteria:~* Patients were known allergy to fluorouracil or 5-fluorouracil.~* Patients with complete lack of known dihydropyrimidine dehydrogenase (DPD) activity.~* Patients with abnormal hepatic and renal function (serum creatinine≤ 1.5 ×ULN; CLcr ≥ 51 mL/min; bilirubin≤ 1.5 ×ULN; AST, ALT≤2.5×ULN)~* Needed to accept phenytoin, warfarin, other coumarin derivatives anticoagulants, folic acid, and CYP2C9 substrates during the research.~* Patients with brain metastases or other metastases of the central nervous system (except those who were treated at least 6 months prior to the start of the study and were stable and asymptomatic).

- Gender: ALL
- Minimum Age: 28 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- capecitabine reference formulation at a single dose of 150 mg (Type: ACTIVE_COMPARATOR): 150 mg of Xeloda® produced by Genentech USA, Inc., a subsidiary of the company, was used as the reference intervention in this study.
- capecitabine test formulation at a single dose of 150 mg (Type: EXPERIMENTAL): The tablet of 150 mg of capecitabine from Qilu Pharmaceutical Co., Ltd. (17H0053DE4, Jinan, Shandong Province, China) was used as the test formulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacological Effects of Crushing Prasugrel in STEMI Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Patients with ST-elevation myocardial infarction undergoing primary PCI~* Age between 18 and 75 years old~Exclusion criteria:~* Age \>75 years~* Weight \<60 Kg~* On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in past 7 days~* Known allergies to aspirin or prasugrel~* Considered at high risk for bleeding~* History of ischemic or hemorrhagic stroke or transient ischemic attack~* On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban, apixaban)~* Treatment with IIb/IIIa glycoprotein inhibitors~* Fibrinolytics within 24 hours~* Known blood dyscrasia or bleeding diathesis~* Known platelet count \<80x106/mL~* Known hemoglobin \<10 g/dL~* Active bleeding~* Hemodynamic instability~* Known creatinine clearance \<30 mL/minute~* Known severe hepatic dysfunction~* Pregnant females\*~  * Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Prasugrel crush (Type: EXPERIMENTAL): Prasugrel 60mg loading dose as crushed tablets
- Prasugrel tablets (Type: ACTIVE_COMPARATOR): Prasugrel 60 mg loading dose as whole tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: FFA-Induced Hypertension and Endothelial Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between the ages of 18 and 65 years.~* Definition: obese = BMI ≥ 30 kg/m2~* Blood pressure \< 140/80 mm Hg and no prior history of hypertension~Exclusion Criteria:~* History of hypertension or previous history of antihypertensive drug therapy.~* Current tobacco use~* Fasting triglyceride levels \> 250 mg/dL during the stabilization period.~* Liver disease (ALT 2.5x \> upper limit of normal), or other significant medical or surgical illness, including myocardial ischemia, congestive heart failure, liver failure, and infectious processes.~* Serum creatinine ≥1.5 mg/dL for males, or ≥ 1.4 mg/dL for females.~* History of drug or alcohol abuse within the last 5 years.~* Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.~* Female subjects are pregnant or breast feeding at time of enrollment into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Intralipid 20%@ 20cc/hour (Type: ACTIVE_COMPARATOR): Intralipid 20% IV infusion at 20cc/hour
- Intralipid 20% @ 40cc/hour (Type: ACTIVE_COMPARATOR): Intralipid 20% IV infusion at 40cc/hour
- Normal Saline infusion @ 40cc/hour (Type: PLACEBO_COMPARATOR): Normal Saline continuous IV infusion at 40cc/hour for 8 hours
- 32-gram oral fat load (Type: ACTIVE_COMPARATOR): 32-gram oral fat load once
- 64-gram oral fat load (Type: ACTIVE_COMPARATOR): 64-gram oral fat load once

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old at the start of Screening Visit~* A documented diagnosis of adult-onset axial SpondyloArthritis (axSpA) and meet the Assessment of SpondyloArthritis International Society (ASAS) criteria for axSpA~* Subjects must have had back pain for at least 12 months before Screening~* No sacroiliitis defined by Modified New York (mNY) criteria on sacroiliac (SI) x-rays~* Active disease at Screening as defined by~  * Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score \>= 4~ * Spinal pain \>= 4 on a 0 to 10 Numerical Rating Scale (NRS)~* Inadequate response to, have a contraindication to, or have been intolerant to at least 2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)~Exclusion Criteria:~* Diagnosis of AS or any other Inflammatory Arthritis~* Prior treatment with any experimental biological agents for treatment of Axial SpondyloArthritis (SpA)~* Exposure to more than 1 tumor necrosis factor (TNF)-antagonist or primary failure to TNF antagonist therapy~* History of or current chronic or recurrent infections~* Subjects with known Tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent Tuberculosis (LTB)~* Recent live vaccination~* Concurrent malignancy or a history of malignancy~* Class III or IV congestive heart failure - New York Heart Association (NYHA)~* Demyelinating disease of the central nervous system~* Female subjects who are breastfeeding, pregnant or plan to become pregnant during the study or within 3 months following the last dose of the investigational product~* Subjects with any other condition which, in the investigator's judgment, would make the subject unsuitable for inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab Pegol 200 mg Q2W (Type: EXPERIMENTAL): Certolizumab Pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards.
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo to Certolizumab Pegol (CZP) injections are administered every 2 weeks from Week 0 onwards.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Rapid Airway Management Positioner

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The 50 subjects will be adult surgical candidates age 18-80, ASA I-III, BMI \> 30 kg/m2 presenting for gastric bypass or laparoscopic gastric banding surgery who require general anesthesia.~Exclusion Criteria:~* Patients will be excluded if it is determined that an awake intubation should be performed. Mallampati IV and ASA IV-V patients will also be excluded, as well as patients with unstable cervical, thoracic and/or lumbar fracture.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Laryngoscopy without RAMP (Type: EXPERIMENTAL): First, laryngoscopy will be preformed utilizing a traditional Macintosh size 4 blade laryngoscope. The view of the laryngeal aperture will be recorded, and a photo will be taken by the Airway Cam™.
- Laryngoscopy with RAMP (Type: EXPERIMENTAL): Next, the Rapid Airway Management Positioner (RAMP) will be positioned and inflated underneath the patient so that the patient is placed in the optimal sniffing position. The investigator will again perform laryngoscopy utilizing the same technique and the laryngeal view will be recorded.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female between, and including 6 and 10 weeks of age at the time of the first vaccination.~* Written informed consent obtained from the parents or guardians of the subject~* Documented HIV status of the subject as confirmed by PCR.~* HIV asymptomatic and HIV mildly symptomatic; Stages I and II disease according to WHO's most recent classification for HIV stages in infants and children.~* Born after a gestation period of 36 to 42 weeks.~Exclusion Criteria:~* Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Previous routine vaccination except OPV, BCG and HBV vaccination at birth~* Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the GI tract or other serious medical condition as determined by the investigator.~* History of allergic disease or reaction likely to be exacerbated by any component of the vaccine.~* Acute disease at time of enrolment.~* Gastroenteritis within 7 days preceding the study vaccine administration.~* Previous confirmed occurrence of RV gastroenteritis.~* Other conditions which in the opinion of the investigator may potentially interfere with interpretation of study outcomes.~* HIV moderately and severely symptomatic: stages III and IV according to WHO's recent classification.~* Administration of immunoglobulins and/or blood products since birth or planned administration during the study period.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 10 Weeks
- Healthy Volunteers: f

Study Arms:
- Rotarix Group (Type: EXPERIMENTAL): Subjects received 3 doses of Rotarix vaccine co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.
- Placebo Group (Type: PLACEBO_COMPARATOR): Subjects received 3 doses of placebo co-administered with routine Tritanrix HepB Hib and Polio Sabin vaccines.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~A. patients belong to either A-1 or A-2 A-1. patients with newly diagnosed acute myeloid leukemia who approve to get induction chemotherapy with (cytarabine plus idarubicin) or (modified Fludarabine + cytarabine + idarubicin ) A-2. patients with newly diagnosed acute lymphoid leukemia who approve to get induction chemotherapy with VPDL (vincristine + prednisolone + daunorubicin + L-asparaginase), C-VPDL (cyclophosphamide + vincristine + prednisolone + daunorubicin + L-asparaginase), or (R)-hyperCVAD ((Rituximab) + cyclophosphamide + vincristine + Adriamycin + dexamethasone) B. Eastern Cooperative Oncology Group performance status score is equal to or more than 2 C. patients who voluntarily sign the agreement~Exclusion Criteria:~A. evidence of proven/probable/possible fungal infection within 30 days before induction chemotherapy B. hypersensitivity to echinocandin C. patients had other malignancy within 5 years D. previous treatment history with chemotherapy, radiation therapy, or immunosuppressive therapy.~E. pregnant or breast-feeding women F. immunodeficient patients including AIDS G. patients with uncontrolled seizure or psychiatric disorder H. clinically significant heart disorder (myocardial infarction within 3 months or left ventricular ejection fraction \< 40%) I. interstitial lung disease J. previous organ transplantation history K. galactose intolerance L. patients who participated this study before.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- micafungin prophylaxis (Type: EXPERIMENTAL): Patients received 50 mg micafungin intravenously once daily from the initiation of induction chemotherapy to recovery of neutrophil count (absolute neutrophil count \> 500/μg for three consecutive days), suspected fungal infection, or occurrence of drug-related toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Naturally Silicon-Rich Water on Bone Metabolism in Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index (BMI) \< 30~* Postmenopausal women with no evidence of osteoporosis by dual energy X-ray absorptiometry (DEXA) scan (T ≥ -2 in the total hip and lumbar spine).~* Pre- or peri-menopausal women with osteopenia but no evidence of osteoporosis by DEXA scan (-1.5 ≤ T ≤ -2 in the total hip and lumbar spine)~* No estrogens or corticosteroids~* No prior history of bisphosphonate medication~* Otherwise in good health with no significant illnesses which could affect bone metabolism such as hypercortisolism, untreated hypothyroidism, treatment with statins or other drugs affecting bone metabolism other than calcium and vitamin D3.~* No change in exercise regimen or calcium intake in the past 3 months.~* Subject must sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or randomization. A subject will be excluded for any condition that might compromise the ability to give truly informed consent for participation in the study.~Exclusion Criteria:~* Males~* Premenopausal women with DEXA T scores ≥ -1.5 or ≤ -2.~* Postmenopausal women with DEXA T scores ≤ -2.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Fiji Water (Type: EXPERIMENTAL): Participants are asked to consume one liter of this silicon-rich water daily for three months.
- Aquafina Water (Type: NO_INTERVENTION): Participants are asked to drink one liter of this deionized water daily for three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Residing in or around Pondicherry and adjoining Tamilnadu areas~* Night blood microfilaria counts \> 10 mf/ml by membrane filtration~* No history of treatment for filarial infection for the last two years at least~* Willing for home visits by the staff of the center~* Willing to give written informed consent~Exclusion Criteria:~* Body weight less than 30 kg~* Hepatic or renal disease as evidenced by clinical or biochemical abnormalities. - concurrent illness like hypertension, diabetes mellitus, cardiac conditions and epilepsy requiring chronic medication~* Psychiatric illness~* Patients under tetracycline or doxycycline therapy~* History of de-worming by albendazole or other anti-helminthic during last one year~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- DEC + ALB sequential (Type: EXPERIMENTAL): Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet at 30 days post treatment sequentially
- DEC + ALB co-admin (Type: EXPERIMENTAL): Diethylcarbamazine 300 mg tablet and albendazole 400 mg tablet per day given orally as single dose for 12 days
- DEC + DOXY co-admin (Type: EXPERIMENTAL): Diethylcarbamazine 300 mg tablet and Doxycycline 100 mg per day given orally as single dose for 12 days
- Diethylcarbamazine (DEC) (Type: ACTIVE_COMPARATOR): Diethylcarbamazine 300 mg tablet as single dose orally per day for 12 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Cannabidiol and ∆-9-THC in Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Exposed to Cannabis at least once in lifetime~Exclusion Criteria:~* Cannabis Naive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Active Canabidiol and Active Delta-9-THC (Type: EXPERIMENTAL): None
- Placebo and Active Delta-9-THC (Type: PLACEBO_COMPARATOR): None
- Active Cannabidiol and Placebo (Type: EXPERIMENTAL): None
- Placebo and Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Plaque-type psoriasis diagnosed \>= 6 months prior~* Plaque-type psoriasis covering at least 10% of total body surface areas~* Psoriasis area-and-severity index score of \>=12 at screening and baseline~* Considered by treating dermatologist to be a candidate for phototherapy or systemic treatment of psoriasis~* Women of childbearing potential and all men must agree to use adequate birth control measures throughout the trials and for 12 months following the last injection of study agent~* Have no history of latent or active tuberculosis (TB)~Exclusion Criteria:~* Currently have nonplaque forms of psoriasis or drug-induced psoriasis~* Women who are pregnant or nursing, or men and women planning pregnancy while enrolled in the study~* Patients who have used any therapeutic agent targeted at reducing IL-12 or IL-23~* Patients who have had a Bacillus Calmette-Guerin (BCG) vaccination within the previous 12 months prior to screening~* Patients who have a history of chronic or recurrent infectious disease or who have or have had a serious infection requiring hospitalization or intravenous antibiotics within the previous 2 months prior to screening~* Patients who have or ever have had a nontuberculous mycobacterial infection or opportunistic infection~* Patients known to be infected with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C~* Patients who have current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, cerebral, or psychiatric disease~* Patients with a malignancy or who have a history of malignancy (with the exception of certain skin cancers and pre-invasive cervical cancer)~* Patients participating in another trial using an investigational agent or procedure~* Systemic immunosuppressants within 4 weeks of the first administration of study agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I: Placebo (Type: PLACEBO_COMPARATOR): None
- Group II: Ustekinumab 45 mg (Type: EXPERIMENTAL): None
- Group III: Ustekinumab 90 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete